Sandu Pharmaceuticals, Inc Stock Price Today (NSE: SANDUPHQ)
Fundamental Score
Sandu Pharmaceuticals, Inc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sandu Pharmaceuticals, Inc share price today is ₹40.69, up +3.01% on NSE/BSE as of 3 August 2026. Sandu Pharmaceuticals, Inc (SANDUPHQ) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹39.61 (Cr). The 52-week high for SANDUPHQ share price is ₹58.28 and the 52-week low is ₹30.00. At a P/E ratio of 22.38x, SANDUPHQ is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 4.13% and a debt-to-equity ratio of 0.01.
Sandu Pharmaceuticals, Inc Share Price Chart — NSE/BSE Historical Performance
Sandu Pharmaceuticals, Inc share price chart: -5.59% return over the past month. 52-week high ₹58.28, 52-week low ₹30.00.
Sandu Pharmaceuticals, Inc — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹40.04 | ₹40.05 | ₹39.00 | ₹39.04 | 841.00 (Cr) | |
| ₹39.01 | ₹40.40 | ₹38.15 | ₹39.50 | 330.00 (Cr) | |
| ₹38.40 | ₹38.40 | ₹38.40 | ₹38.40 | 200.00 (Cr) | |
| ₹39.09 | ₹40.00 | ₹38.00 | ₹38.00 | 646.00 (Cr) | |
| ₹40.08 | ₹40.80 | ₹39.30 | ₹39.30 | 541.00 (Cr) | |
| ₹40.95 | ₹40.95 | ₹38.38 | ₹39.55 | 2.26K (Cr) | |
| ₹38.16 | ₹38.16 | ₹38.16 | ₹38.16 | 0.00 (Cr) | |
| ₹41.49 | ₹41.49 | ₹37.30 | ₹38.16 | 696.00 (Cr) | |
| ₹39.52 | ₹40.99 | ₹39.52 | ₹39.62 | 214.00 (Cr) | |
| ₹41.50 | ₹41.50 | ₹40.25 | ₹40.51 | 785.00 (Cr) |
Sandu Pharmaceuticals, Inc — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹41.00 | ₹42.00 | ₹37.30 | ₹39.04 | -4.78% | |
| ₹42.45 | ₹49.00 | ₹39.85 | ₹41.00 | -3.42% | |
| ₹43.00 | ₹47.95 | ₹36.10 | ₹42.00 | -2.33% | |
| ₹35.50 | ₹50.00 | ₹31.77 | ₹44.00 | +23.94% | |
| ₹34.00 | ₹38.70 | ₹30.00 | ₹30.52 | -10.24% | |
| ₹36.90 | ₹42.00 | ₹32.86 | ₹35.00 | -5.15% | |
| ₹37.90 | ₹42.40 | ₹30.55 | ₹34.40 | -9.23% | |
| ₹41.90 | ₹42.98 | ₹36.76 | ₹37.43 | -10.67% | |
| ₹46.00 | ₹46.25 | ₹37.00 | ₹37.80 | -17.83% | |
| ₹46.50 | ₹46.95 | ₹43.00 | ₹44.76 | -3.74% | |
| ₹48.99 | ₹50.50 | ₹45.06 | ₹46.64 | -4.80% | |
| ₹48.37 | ₹58.28 | ₹46.08 | ₹48.99 | +1.28% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Micro-cap Ayurvedic play with limited growth, significant liquidity risk, and no recent catalysts.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The most recent news relates to the closure of the trading window on March 21, 2026.
CORE STORY (THE REAL GAME)
Sandu Pharmaceuticals is an Ayurvedic medicine manufacturer attempting to capitalize on the growing global interest in alternative medicine and the increasing healthcare spending in India. The core narrative is a play on the 'pharmacy of the world' theme, but specifically within the Ayurvedic segment.
- Dividend yield of 2.47%
- P/E ratio below industry average
- Potential for growth in Ayurvedic medicine market
- Stronger-than-expected earnings
- New product launches
- Increased government support for Ayurvedic medicine
- Micro-cap with limited liquidity
- Slow revenue growth
- High dependence on a niche market
No significant FII/DII activity. Promoter holding stable at 42.9%.
The Indian pharmaceutical industry is projected to grow to $130 billion by 2030, but Sandu's ability to capture a meaningful share of this growth is questionable.
Yes, Free Cash Flow 5Y: ₹6.06 Cr
In the next 3-6 months, Sandu's performance will likely be driven by its ability to maintain sales in a competitive market. Any significant disruption in sales or increase in costs could negatively impact its profitability.
Primary Thesis Risk
Lack of liquidity and slow growth make this a risky investment.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sandu Pharmaceuticals, Inc Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sandu Pharmaceuticals, Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SANDUPHQ across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Attractive Valuation (P/E: 22.38 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (19.76%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (25.09x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (4.13%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.41%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (4.01%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-87.88%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (3.54% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Limited Institutional Interest (FII+DII: 0.01%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Sandu Pharmaceuticals, Inc vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sandu Pharmaceuticals, Inc with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sandu Pharmaceuticals, IncSandu Pharmaceu...Selected✓ SANDUPHQ • 524703 | 27.5/100 | ₹40.69₹41 | ₹39.61₹39.61 | 22.38Average 22.4 Average | 4.13%Poor 4.13% Poor | 6.41%Poor 6.41% Poor | 0.01Excellent 0.0 Excellent | 10.18%Good 10.18% Good | 3.54%Average 3.54% Average | 1.95% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Sandu Pharmaceuticals, Inc PE Ratio History
Historical price-to-earnings ratio for SANDUPHQ — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.51 | ₹57.26 | 37.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sandu Pharmaceuticals, Inc Dividend History
Annual cash dividends paid by SANDUPHQ — dividend yield 1.95%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹0.77 Cr |
| FY 2024 | ₹0.72 Cr |
| FY 2023 | ₹0.66 Cr |
| FY 2022 | ₹0.32 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Sandu Pharmaceuticals, Inc Quarterly Performance
Latest quarterly metrics for SANDUPHQ — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.76%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-87.88%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
3.54%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
10.18%
Compounded annual net profit growth over 5 years
Sandu Pharmaceuticals, Inc Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SANDUPHQ — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Sandu Pharmaceuticals, Inc Financial Statements
Annual income statement, balance sheet and cash flow for Sandu Pharmaceuticals, Inc (SANDUPHQ) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Sandu Pharmaceuticals, Inc
About SANDUPHQ (Sandu Pharmaceuticals, Inc)
Sandu Pharmaceuticals, Inc. is a pioneering force in the realm of holistic wellness, meticulously crafting a diverse portfolio of therapeutic solutions rooted in the ancient wisdom... of Ayurveda. We are committed to providing high-quality, all-natural remedies designed to harmonize the mind, body, and spirit. Our products, born from time-tested formulations and rigorous scientific research, address a wide spectrum of health concerns, from promoting digestive harmony and boosting immunity to enhancing cognitive function and supporting overall vitality. SANDUPHQ believes in the power of nature and is devoted to unlocking the potential of natural ingredients. Our comprehensive range of products showcases our dedication to Ayurvedic principles and innovative solutions. These encompass a variety of herbal concoctions, rejuvenating tonics, potent blood purifiers, and revitalizing granules meticulously designed to restore equilibrium and enhance well-being. Each SANDUPHQ product is manufactured using sustainably sourced ingredients and adhering to stringent quality control measures, thereby ensuring potency, safety, and efficacy. We strive to honor the integrity of Ayurveda while simultaneously embracing modern advancements to provide effective and reliable health solutions. Driven by a passion for promoting holistic wellness, SANDUPHQ is more than just a pharmaceutical company, we are a trusted partner on your path to optimal health. Our unwavering commitment to quality, sustainability, and innovation underscores our mission to empower individuals to take control of their well-being. With SANDUPHQ, you can discover the transformative power of Ayurveda and embark on a journey towards lasting health and vitality, allowing you to live your life to its fullest potential.
Company Details
Key Leadership
Corporate Events
SANDUPHQ Share Price: Frequently Asked Questions
What is the current share price of Sandu Pharmaceuticals, Inc?
Sandu Pharmaceuticals, Inc (SANDUPHQ) trades at ₹40.69 on NSE and BSE. Market cap ₹39.61 (Cr). Educational data only.
What is the P/E ratio of Sandu Pharmaceuticals, Inc?
Sandu Pharmaceuticals, Inc has a P/E of 22.38x vs industry average 34.89x.
What is the Bull Run score for Sandu Pharmaceuticals, Inc?
Sandu Pharmaceuticals, Inc has a Bull Run score of 27.5/100 based on 25+ financial parameters.
Does Sandu Pharmaceuticals, Inc pay dividends?
Sandu Pharmaceuticals, Inc has a dividend yield of 1.95%. Past dividends don't guarantee future payments.
What is the ROE of Sandu Pharmaceuticals, Inc?
Sandu Pharmaceuticals, Inc has ROE of 4.13%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sandu Pharmaceuticals, Inc?
Sandu Pharmaceuticals, Inc has debt-to-equity of 0.01.
Is Sandu Pharmaceuticals, Inc a good investment?
Bull Run gives Sandu Pharmaceuticals, Inc a score of 27.5/100. This is not investment advice — consult a SEBI-registered advisor.